Vividion Therapeutics
CA - San DiegoBiotechnology
Focus: Vividion Therapeutics is an early-stage oncology-focused biotech company leveraging proprietary screening technology to identify novel small-molecule therapeutics for advanced solid tumors. Founded in 2023 and publicly traded, the company is in the pre-clinical-to-early-clinical phase with a lean operational footprint.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
7+1 this month
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Should You Work at Vividion Therapeutics?
AI assessmentVividion is a high-risk, early-stage pure-play oncology discovery engine suited for scientists and operators seeking equity upside and hands-on impact in a nascent public biotech, not stability-seeking career builders.
Why Work Here
- Join a newly public oncology biotech with proprietary screening technology differentiating its discovery approach in a high-value therapeutic area.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
VVD-130850
Advanced Solid TumorsClinical Trials (1)
NCT06188208A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Phase 1Help build intelligence for Vividion Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.